Biblio

Author Title [ Type

] Year

Filters: Author is Tripepi, Giovanni [Clear All Filters]

Journal Article

Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.

Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, et al. Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study. Am J Hematol. 2021.

Martino M, Gori M, Moscato T, Naso V, Ferreri A, Provenzano F, Loteta B, Sanguedolce MCristina, Console G, Dattola A, et al. The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts. Biol Blood Marrow Transplant. 2019.

Martino M, Gori M, Porto G, Pellicano M, Santoro L, Verduci C, Canale FAntonio, Loteta B, Moscato T, Alati C, et al. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023.

Martino M, Gori M, Porto G, Pellicano M, Santoro L, Verduci C, Canale FAntonio, Loteta B, Moscato T, Alati C, et al. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023.

Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, et al. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials. Am J Hematol. 2021.

Morabito F, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, et al. TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Am J Hematol. 2021.